Anion-Transport Mechanism of a Triazole-Bearing Derivative of Prodigiosine: A Candidate for Cystic Fibrosis Therapy

Authors: Claudia Cossu, Michele Fiore, Debora Baroni, Valeria Capurro, Emanuela Caci, Maria Garcia-Valverde, Roberto Quesada and Oscar Moran. Front. Pharmacol., 07 August 2018 Cystic fibrosis (CF) is a genetic lethal disease, originated from the defective function of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel. CF mutations affect CFTR protein through a variety of molecular mechanisms which result in different functional defects. Current therapeutic approaches are ...

July 2018 Newsletter

The threat of antimicrobial resistance During the last decades an increasing ability of microorganisms to resist to the major antimicrobials used has been recognized (EC COM (2011) 748). This phenomenon, neither surprising nor new, is becoming a global public health problem, as antimicrobial resistance (AMR) accumulates and accelerates in time. AMR is referred to microbes that have acquired the ability ...

Small molecule anionophores promote transmembrane anion permeation matching CFTR activity.

Elsa Hernando, Valeria Capurro, Claudia Cossu, Michele Fiore, María García-Valverde, Vanessa Soto-Cerrato, Ricardo Pérez-Tomás, Oscar Moran, Olga Zegarra-Moran & Roberto Quesada
Abstract: Anion selective ionophores, anionophores, are small molecules capable of facilitating the transmembrane transport of anions. Inspired in the structure of natural product prodigiosin, four novel anionophores 1a-d, including a 1,2,3-triazole group, were prepared. These compounds proved highly efficient anion exchangers in model phospholipid liposomes. …

January 2018 Newsletter

It is a matter of bicarbonateOscar Moran - Istituto di Biofisica, CNR, Genova, ItalyCystic fibrosis (CF) is a genetic disease that affects several organs. The malfunction or lack of the protein CFTR severely reduces the an­ion transport in the apical membranes of epi­thelia, that form the lumen of internal organs, like bronchi, intestine, sweet glands and pan­creas ducts. One of ...

June 2017 Newsletter

A brief history of the cystic fibrosis therapy…Oscar Moran - Istituto di Biofisica, CNR, Genova, ItalyCystic fibrosis (CF) is the most common se­vere recessive hereditary disease in Cauca­sians. In Europe, CF affects 1 in 2000–3000 newborns. CF has a complex and greatly variable clinical expression, involving airways, pancreas, male genital system, intestine, liver, bone, and kidney. Some of the disease ...

December 2016 Newsletter

TAT-CF: Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transportersTAT-CF is a collaborative project coordinated by the University of Burgos, which has been formally launched on 1st of January 2016 with an expected duration of 36 months. Apart from the University of Burgos, the consortium is formed by 3 research centres: CSIC-Consejo Superior ...